SRR25617831
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR25617852 | — | B | 0.898 |
| 2 | TCGA-DQ-7591-01A-11R-2081-07 | — | — | 0.875 |
| 3 | SRR25617823 | — | D | 0.870 |
| 4 | SRR25617910 | — | B | 0.870 |
| 5 | MDT-AP-1162 | Med | Medulloblastoma | 0.867 |
| 6 | SRR25617851 | — | B | 0.837 |
| 7 | SRR650131 | — | — | 0.837 |
| 8 | SRR10900593 | — | — | 0.823 |
| 9 | AUR-AD9G-TTP1-B-4-0-R-A584-39 | — | D | 0.822 |
| 10 | MDT-AP-1327 | Med | Medulloblastoma | 0.821 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.360 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.320 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.310 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.280 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.190 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.100 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.060 | Inavolisib | — uncovered |